drugset

drugset / Trial / NCT00810004

Maintenance Treatment of Iron Deficiency in IBD Patients

NCT00810004 ↗

Phase 3 Completed 245 enrolled Vifor Pharma Parexel · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

The aim of this study is to evaluate the treatment of iron deficiency in IBD patients.

Timeline

Start: 2009-02
Primary completion: 2010-10
Completion: 2010-10

Publications

Evstatiev R, Alexeeva O, Bokemeyer B, Chopey I, Felder M, Gudehus M, Iqbal T, Khalif I, Marteau P, Stein J, Gasche C; FERGI Study Group. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Mar;11(3):269-77. doi: 10.1016/j.cgh.2012.10.013. Epub 2012 Oct 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ferric carboxymaltose	Other / unclassified	—	Intravenous

Indications